

Freedom of Information Request	FOI 22-405	20 <sup>th</sup> September 2022
--------------------------------	------------	---------------------------------

**Q1. Does your trust treat myelofibrosis? If not, which other trust do you refer these patients to?**

Yes. However, patients who require an allogeneic stem cell transplant are referred to Cardiff and Vale University Health Board for treatment.

**Q2. a) Please provide the total number of patients treated in the last 6 months (or the latest 6 months data you have available) for myelofibrosis (ICD10 code D47.4).**

18.

**b) How many of these patients were above age 65?**

14.

**Q3. How many myelofibrosis patients were treated in the past 6 months with Ruxolitinib?**

6.

**Q4. a) How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?**

11.

**b) Of these patients, how many were treated in the past 6 months (or the latest 6 months data you have available) with:**

- **Hydroxyurea** 6
- **Fedratinib** 0
- **Received No treatment** <5

\* Please note where less than five (5) patients have been identified, Section 40 of the Freedom of Information Act 2000 has been applied as the Health Board cannot provide the exact numbers due to the low numbers of individuals involved (5 or less). The Health Board believes there is a potential risk of individuals being able to be identified, when considered with other information already available within the public domain, if this was disclosed. Therefore, the data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

**Q5. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part.**

The Health Board is not currently participating in any studies for the treatment of myelofibrosis.